A Phase 2 interventional study of TPX-115 and Cryopreserving hyaluronic acid medium in Partial Thickness Rotator Cuff Tears, sponsored by Tego Science, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Tego Science, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Rotator Cuff Injuries with a site in United States — 40 open to participants now, 50 under way, none of them phase 3. Rotator Cuff Injuries · United States.
Among the 168 studies in Rotator Cuff Injuries with a site in United States, this one is the 62nd largest by planned enrollment of the 130 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 26 of the 49 other live ones, and was the 162nd registered.
631 studies on the registry are indexed under Rotator Cuff Injuries; 156 are open to participants now.
Browse Rotator Cuff Injuries studies →40 of the 168 studies in Rotator Cuff Injuries with a site in United States are open now. Recruiting first, the newest first:
Joseph W. Galvin · Sites in United States
Ages 18–99
The Cleveland Clinic · Sites in United States
Ages 18–75
ZuriMED Technologies Inc. · Sites in United States
Ages 30–70
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Anika Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 5 · Phase 4 22
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.
Median enrollment 60 across the 130 interventional studies, 77 across the 38 observational. Of the 86 that completed or were terminated, 28 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 168 have an industry lead sponsor. The 10 most frequent:
Tego Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Tego Science, Inc. has 4 studies filed under Rotator Cuff Injuries — fewer than ten, so there is no comparison to draw.
29 of the studies in Rotator Cuff Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06735170University of MinnesotaTuberoplasty Versus Balloon Spacer | 2026-11-26 |
| NCT07851233Rothman Institute OrthopaedicsPatient Education and Sling Use After Shoulder Surgery | 2026-11-30 |
| NCT06039345University of UtahShoulder RFA Pilot Study | 2026-12 |
| NCT05011331Rhode Island HospitalThe Effect of a Custom Pillow on Sleep Quality in Patients With Nonoperative Rotator Cuff Syndrome | 2026-12 |
| NCT06669741Texas Bone and JointClinical Outcomes Related to Arthroscopic Rotator Cuff Repair Recovery Using Incrediwear | 2026-12-01 |
Add all 29 to your calendar (.ics) → With an account.
Among the 168 studies in Rotator Cuff Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the efficacy and safety of allogeneic dermal fibroblasts (TPX-115) compared to placebo in patients with Partial-Thickness Rotator Cuff Tear(PTRCT).
Primary endpoint is to evaluate the efficacy of TPX-115 compared to placebo, as measured by improvement in the Constant-Murley Score (CMS) in patients with PTRCT.
Secondary endpoints are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet the following laboratory criteria, with results within 5% of the specified normal reference ranges:
Exclusion Criteria:
Patients who have any of the following diseases at screening or have medical history of past:
Note: Suitable contraceptive methods are condom, sponge, gel, diaphragm for contraception, hormonal contraceptives, intrauterine device, etc. Periodic abstinence (eg, calendar method, ovulation method, symptom body temperature method, post-ovulation method) and restraint are not considered an accepted method of contraception. However, women unable to become pregnant due to menopause (at least 12 months since last menstrual period) can participate in the study with negative pregnancy test results.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: TPX-115
Biological: TPX-115
Biological: TPX-115
Other: Cryopreserving hyaluronic acid medium
Drug: Saline
Single injection of Allogeneic dermal fibroblasts (TPX-115) via ultrasound-guided intratendinous injection
Medium included in TPX-115 for cryopreservation
Saline
Change from baseline in Constant-Murley Score(CMS) at Week 24
The CMS is calculated from 0 (worst function) to 100 (best function) points
Time frame: Baseline, Week 24
Change from baseline in Constant-Murley Score(CMS) at Weeks 4, 12, and 52
The CMS is calculated from 0 (worst function) to 100 (best function) points
Time frame: Baseline, Week 4, Week 12, Week 52
Increase of at least 8 points from baseline in Constant-Murley Score(CMS) at Week 24
The CMS is calculated from 0 (worst function) to 100 (best function) points
Time frame: Baseline, Week 24
Change from baseline in Visual Analogue Scale(VAS) (0 to 10 cm) score for shoulder pain at Weeks 4, 12, 24, and 52
The VAS is a horizontal line, 10 cm in length, with anchor statements on the left (0 cm; meaning 'no pain') and on the right (10cm; meaning 'extreme pain')
Time frame: Baseline, Week 4, Week 12, Week 24, Week 52
Change from baseline in Range of Motion(ROM) in the affected shoulder at Weeks 4, 12, 24, and 52
Time frame: Baseline, Week 4, Week 12, Week 24, Week 52
Change from baseline in American Shoulder and Elbow Surgeons(ASES) score at Weeks 4, 12, 24, and 52
The ASES score is calculated from zero (worst) to 100 (best) points
Time frame: Baseline, Week 4, Week 12, Week 24, Week 52
Change from baseline in Simple Shoulder Test at Weeks 4, 12, 24, and 52
Time frame: Baseline, Week 4, Week 12, Week 24, Week 52
Change from baseline in tear size (mm) on MRI at Week 52
Time frame: Baseline, Week 52
Change from baseline in tendon thickness (mm) on MRI at Week 52
Time frame: Baseline, Week 52
Change from baseline in tear/footprint (%p) on MRI at Week 52
Time frame: Baseline, Week 52
Change from baseline in tendinosis on MRI at Week 52
The grade of tendinosis is assessed from zero (normal) to 3 (marked) by a central reader only (independent evaluator).
Time frame: Baseline, Week 52
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TPX-115
Tego Science, Inc.